DM Capital
DM Capital Ltd. is a venture capital and private equity firm founded in 2001 and headquartered in Shenzhen, China, with additional offices in major cities including Beijing, Guangzhou, and Zurich. The firm specializes in early-stage and growth investments, primarily focusing on the healthcare sector. Its investment interests encompass a wide range of areas such as innovative medical technologies, artificial intelligence, biomedicine, genetic technology, and advanced healthcare equipment. DM Capital also engages in industrial investments and provides financial advisory services. As the parent company of DM Healthcare Investment Co., Ltd., it further extends its investment activities to overseas healthcare industries. The firm is committed to fostering technology innovation and creating value through strategic investments in companies involved in health technology, biopharmaceuticals, and medical devices. Through its subsidiary, DM Fund Management Limited, DM Capital actively manages funds that target public Chinese companies listed on international exchanges, while also facilitating mergers and acquisitions between Chinese and Western markets.
mimiX Biotherapeutics aims to deliver the next generation biofabrication technology, that will enable tissue manufacturing for therapeutic and diagnostic purposes. mimiX Biotherapeutics will make this vision a reality by providing an ultra-fast biomanufacturing technology capable of creating point-of-care patient-specific biological tissue equivalents for regenerative, personalized, and precision medicine.
Rege Nephro Co., Ltd. engages in the research and development, production, and marketing of renal disease therapeutics using nephron progenitor cells. It also produces kidney organoids capable of nephrotoxicity screening for drug discovery in applied research. The company was founded in 2019 and is based in Kyoto, Japan.
Shanggongyixin is a Beijing Based Healthcare Start Up.
Sigilon Therapeutics, Inc., a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
IVIVA Medical, Inc. develops bio-artificial platforms and systems to provide therapies. It develops alternative end-state renal disease therapies that alleviate donor organ demand for patients; disease and pathology modeling; and bioreactor systems. The company was incorporated in 2013 and is based in Beverly, Massachusetts.
uLab Systems Inc. is a developer of innovative software technology designed for digital dental treatment planning specifically for orthodontists. Founded in 2015 and based in Redwood City, California, with an additional office in Shanghai, China, the company offers a platform that allows orthodontists to create customized treatment plans tailored to individual patient needs. Utilizing proprietary architecture and artificial intelligence, uLab enables practitioners to develop chairside treatment plans in under five minutes, significantly streamlining the process. The technology also facilitates the creation of aligner movement plans and the printing of custom aligners, helping orthodontists manage their treatment plans more efficiently, lower laboratory costs, and expedite the delivery of orthodontic appliances.
Guangzhou eBrace Biotechnology Co., Ltd. specializes in the research, development, production, and sale of orthodontic biological materials and digital 3D printing technologies. Founded in 2010 and headquartered in Guangzhou, China, the company offers a range of products including 3D custom printed orthodontic teeth, dentures, and personalized lingual and bracketless invisible appliances. eBrace is committed to providing detailed and accurate dental solutions, leveraging advanced 3D printing equipment to meet the needs of its customers in the orthodontics sector.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.